Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.
Fiche publication
Date publication
janvier 2015
Journal
Journal of market access & health policy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Roblin X, Attar A, Lamure M, Savarieau B, Brunel P, Duru G, Peyrin-Biroulet L
Lien Pubmed
Résumé
The use of pharmacokinetics is associated with cost savings in anti-tumor necrosis factor (anti-TNF) therapy, but the long-term cost savings in a large cohort of Crohn's disease (CD) patients are unknown.
Mots clés
Crohn's disease, adalimumab, cost saving, infliximab, pharmacokinetics
Référence
J Mark Access Health Policy. 2015 ;3: